Oral Semaglutide coming down the pipeline for weight loss?
Exciting developments in the field of weight management have emerged over the past few years utilizing GLP-1 medications that were originally only used for the treatment of Type 2 diabetes.
What is Semaglutide?
Semaglutide is a medication that belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone naturally produced in the body that helps regulate blood sugar levels by stimulating the release of insulin and reducing the production of glucose. Semaglutide is a synthetic form of GLP-1 that is used to treat type 2 diabetes and obesity.
Semaglutide has gained significant attention as an effective weight-loss treatment due to its ability to mimic a hormone called glucagon-like peptide-1(GLP-1), which targets the brain areas responsible for regulating appetite and food intake.
Currently available in various forms, including Ozempic (used for diabetes treatment) and Wegovy (a higher-dose version approved for weight loss) as weekly injections, Semaglutide is also offered in a low-dose oral form for type 2 diabetes under the brand name Rybelsus. Our clinic offers Semaglutide medications to our patients for managing both diabetes and weight loss through ReSet.
Results of a current trial just released
Novo Nordisk, a leading pharmaceutical company, has recently unveiled groundbreaking results from its Phase 3 clinical trial for a daily oral form of semaglutide.
The trial, which involved 667 adults diagnosed as overweight or obese, with an average weight of 232.4 pounds, or 105.4 kg, individuals treated with 50 mg of oral semaglutide lost 17.4% on average of their body weight after 68 weeks, in contrast to a 1.8% reduction observed in the placebo group.
Additionally, nearly 90% of the participants achieved a weight loss of at least 5%, compared to only 24.5% in the placebo group. showcased a remarkable weight loss of 15.1% among participants who received the oral treatment of 50 mg daily over a period of 68 weeks. In contrast, the placebo group only experienced a 2.4% reduction in body weight.
Martin Holst Lange, executive vice president for Development at Novo Nordisk. states the following,
“We are very pleased with the weight loss demonstrated by the once-daily oral formulation of semaglutide in obesity. The results show comparable weight loss as in the STEP 1 trial with injectable semaglutide 2.4 mg in obesity branded as Wegovy.®”
He goes on to say:
”The choice between a daily tablet or weekly injection for obesity has the potential to offer patients and healthcare providers the opportunity to choose what best suits individual treatment preferences”.
Click here to read the press release
Our clinic is here to help in your weight loss journey
At DETS, we focus on your wellness, not illness. We help you in becoming the best version of YOU. If you need to be evaluated for potential health concerns related to diabetes, pre-diabetes, thyroid, or weight loss concerns due to metabolic changes, we are here to help. Our providers listen to you, take appropriate action in learning what is happening with your body, and create a treatment plan that will assist you to become as healthy as possible. Contact us today to set up an appointment.
